Terms: = Breast cancer AND PAM50 AND Diagnosis
42 results:
1. Molecular subtyping improves breast cancer diagnosis in the Copenhagen breast cancer Genomics Study.
Berg T; Jensen MB; Celik A; Talman ML; Misiakou MA; Knoop AS; Nielsen FC; Ejlertsen B; Rossing M
JCI Insight; 2024 Apr; 9(7):. PubMed ID: 38587073
[TBL] [Abstract] [Full Text] [Related]
2. NCAPH drives breast cancer progression and identifies a gene signature that predicts luminal a tumour recurrence.
Mendiburu-Eliçabe M; García-Sancha N; Corchado-Cobos R; Martínez-López A; Chang H; Hua Mao J; Blanco-Gómez A; García-Casas A; Castellanos-Martín A; Salvador N; Jiménez-Navas A; Pérez-Baena MJ; Sánchez-Martín MA; Abad-Hernández MDM; Carmen SD; Claros-Ampuero J; Cruz-Hernández JJ; Rodríguez-Sánchez CA; García-Cenador MB; García-Criado FJ; Vicente RS; Castillo-Lluva S; Pérez-Losada J
Clin Transl Med; 2024 Feb; 14(2):e1554. PubMed ID: 38344872
[TBL] [Abstract] [Full Text] [Related]
3. LncRNA SOX9-AS1 triggers a transcriptional program involved in lipid metabolic reprogramming, cell migration and invasion in triple-negative breast cancer.
Cisneros-Villanueva M; Fonseca-Montaño MA; Ríos-Romero M; López-Camarillo C; Jiménez-Morales S; Langley E; Rosette-Rueda AS; Cedro-Tanda A; Hernández-Sotelo D; Hidalgo-Miranda A
Sci Rep; 2024 Jan; 14(1):1483. PubMed ID: 38233470
[TBL] [Abstract] [Full Text] [Related]
4. Application Of Multigene Panel Detection In breast cancer.
Zhao Y; Xiong D; Yang B; Xia S; Zhang X
J Pak Med Assoc; 2023 Sep; 73(9):1862-1868. PubMed ID: 37817699
[TBL] [Abstract] [Full Text] [Related]
5. Molecular characteristics of breast tumors in patients screened for germline predisposition from a population-based observational study.
Nacer DF; Vallon-Christersson J; Nordborg N; Ehrencrona H; Kvist A; Borg Å; Staaf J
Genome Med; 2023 Apr; 15(1):25. PubMed ID: 37060015
[TBL] [Abstract] [Full Text] [Related]
6. Predicting hormone receptors and pam50 subtypes of breast cancer from multi-scale lesion images of DCE-MRI with transfer learning technique.
Ming W; Li F; Zhu Y; Bai Y; Gu W; Liu Y; Sun X; Liu X; Liu H
Comput Biol Med; 2022 Nov; 150():106147. PubMed ID: 36201887
[TBL] [Abstract] [Full Text] [Related]
7. Obesity and breast cancer Metastasis across Genomic Subtypes.
Olsson LT; Walens A; Hamilton AM; Benefield HC; Fleming JM; Carey LA; Hursting SD; Williams KP; Troester MA
Cancer Epidemiol Biomarkers Prev; 2022 Oct; 31(10):1944-1951. PubMed ID: 35973227
[TBL] [Abstract] [Full Text] [Related]
8. Single-cell RNA sequencing reveals the characteristics of cerebrospinal fluid tumour environment in breast cancer and lung cancer leptomeningeal metastases.
Ruan H; Wang Z; Sun Z; Wei J; Zhang L; Ju H; Wang T; Zhang C; Guan M; Pan S
Clin Transl Med; 2022 Jun; 12(6):e885. PubMed ID: 35678121
[TBL] [Abstract] [Full Text] [Related]
9. Comprehensive Characterization of the Function of Metabolic Genes and Establishment of a Prediction Model in breast cancer.
Yu R; Peng M; Zhao S; Wang Z; Ma Y; Zhang X; Lv X; Wang S; Ju S; Zhao R; Zhou Q; Lian W
Dis Markers; 2022; 2022():3846010. PubMed ID: 35493305
[TBL] [Abstract] [Full Text] [Related]
10. Population-based Study of Prosigna-pam50 and Outcome Among Postmenopausal Women With Estrogen Receptor-positive and HER2-negative Operable Invasive Lobular or Ductal breast cancer.
Lænkholm AV; Jensen MB; Eriksen JO; Roslind A; Buckingham W; Ferree S; Nielsen T; Ejlertsen B
Clin Breast Cancer; 2020 Aug; 20(4):e423-e432. PubMed ID: 32253134
[TBL] [Abstract] [Full Text] [Related]
11. What Is the Real Impact of Estrogen Receptor Status on the Prognosis and Treatment of HER2-Positive Early breast cancer?
Brandão M; Caparica R; Malorni L; Prat A; Carey LA; Piccart M
Clin Cancer Res; 2020 Jun; 26(12):2783-2788. PubMed ID: 32046997
[TBL] [Abstract] [Full Text] [Related]
12. GSIAR: gene-subcategory interaction-based improved deep representation learning for breast cancer subcategorical analysis using gene expression, applicable for precision medicine.
Sur C
Med Biol Eng Comput; 2019 Nov; 57(11):2483-2515. PubMed ID: 31591679
[TBL] [Abstract] [Full Text] [Related]
13. Research-based pam50 signature and long-term breast cancer survival.
Pu M; Messer K; Davies SR; Vickery TL; Pittman E; Parker BA; Ellis MJ; Flatt SW; Marinac CR; Nelson SH; Mardis ER; Pierce JP; Natarajan L
Breast Cancer Res Treat; 2020 Jan; 179(1):197-206. PubMed ID: 31542876
[TBL] [Abstract] [Full Text] [Related]
14. Bimodal age distribution at diagnosis in breast cancer persists across molecular and genomic classifications.
Allott EH; Shan Y; Chen M; Sun X; Garcia-Recio S; Kirk EL; Olshan AF; Geradts J; Earp HS; Carey LA; Perou CM; Pfeiffer RM; Anderson WF; Troester MA
Breast Cancer Res Treat; 2020 Jan; 179(1):185-195. PubMed ID: 31535320
[TBL] [Abstract] [Full Text] [Related]
15. Deep learning with evolutionary and genomic profiles for identifying cancer subtypes.
Lin CY; Ruan P; Li R; Yang JM; See S; Song J; Akutsu T
J Bioinform Comput Biol; 2019 Jun; 17(3):1940005. PubMed ID: 31288637
[TBL] [Abstract] [Full Text] [Related]
16. On-treatment biomarkers can improve prediction of response to neoadjuvant chemotherapy in breast cancer.
Bownes RJ; Turnbull AK; Martinez-Perez C; Cameron DA; Sims AH; Oikonomidou O
Breast Cancer Res; 2019 Jun; 21(1):73. PubMed ID: 31200764
[TBL] [Abstract] [Full Text] [Related]
17. Characterization of molecular scores and gene expression signatures in primary breast cancer, local recurrences and brain metastases.
Bustamante Eduardo M; Popovici V; Imboden S; Aebi S; Ballabio N; Altermatt HJ; Günthert A; Jaggi R
BMC Cancer; 2019 Jun; 19(1):549. PubMed ID: 31174485
[TBL] [Abstract] [Full Text] [Related]
18. Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups.
Rueda OM; Sammut SJ; Seoane JA; Chin SF; Caswell-Jin JL; Callari M; Batra R; Pereira B; Bruna A; Ali HR; Provenzano E; Liu B; Parisien M; Gillett C; McKinney S; Green AR; Murphy L; Purushotham A; Ellis IO; Pharoah PD; Rueda C; Aparicio S; Caldas C; Curtis C
Nature; 2019 Mar; 567(7748):399-404. PubMed ID: 30867590
[TBL] [Abstract] [Full Text] [Related]
19. Quantification of intrinsic subtype ambiguity in Luminal A breast cancer and its relationship to clinical outcomes.
Kumar N; Zhao D; Bhaumik D; Sethi A; Gann PH
BMC Cancer; 2019 Mar; 19(1):215. PubMed ID: 30849944
[TBL] [Abstract] [Full Text] [Related]
20. Differences in molecular features of triple-negative breast cancers based on the age at diagnosis.
Gulbahce HE; Bernard PS; Weltzien EK; Factor RE; Kushi LH; Caan BJ; Sweeney C
Cancer; 2018 Dec; 124(24):4676-4684. PubMed ID: 30311638
[TBL] [Abstract] [Full Text] [Related]
[Next]
